ArticleScientific reports2025
Long term efficacy of adjuvant chemotherapy in elderly patients with early stage breast cancer assessed through SEER database analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current guidelines lack definitive recommendations on the use of chemotherapy for early-stage breast cancer in patients aged over 70. Clinical decision-making on chemotherapy for elderly breast cancer remains challenging because of insufficient large-scale, long-term outcomes. We conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results database from 2010 to 2020 to investigate early-stage breast infiltrating ductal carcinoma in patients aged 70 to 79. Propensity score matching (PSM) with a ratio of 1:1 and caliper of 0.02 standard deviation of propensity score was employed to address covariate imbalance. Univariate and multivariate analyses were performed to assess the impact of chemotherapy on breast cancer-specific survival (BCSS) and overall survival (OS). We identified a total of 11,792 patients with complete information about breast cancer, who underwent surgical treatment and received systemic therapy after surgery. Among them, 3,490 patients received chemotherapy. After PSM, we obtained a matched cohort consisting of 3,156 patients where the characteristics between the two groups were balanced except for molecular subtypes. In the matched dataset, no significant differences were observed in BCSS (P = 0.118) and OS (P = 0.119) between the two groups based on Kaplan-Meier survival analysis. Similarly, multivariate COX analysis revealed that chemotherapy did not significantly reduce the risk of BCSS (HR: 1.212; 95% CI: [0.958-1.533], P = 0.109) and OS (HR: 0.888; 95% CI: [0.765-1.031], P = 0.12). Stratified analyses based on molecular subtypes revealed that chemotherapy did not confer a favorable prognosis in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2(HER2)-negative breast cancer in stages I and IIa, as well as in patients with HR+HER2+ breast cancer in stages I. Chemotherapy may not confer a discernible benefit for all elderly patients with breast cancer. Nevertheless, de-escalating chemotherapy could be considered as a preferable alternative for older individuals diagnosed with HR+HER2- breast cancer in stages I and IIa or HR+HER2+ breast cancer in stages I.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.